To the content
2 . 2021

Glyclazide MR: obvious benefits

Abstract

Sulfonylureas are effective oral hypoglycemic agents that have been used for a long time in clinical practice. Although they all share a common mode of action, their pharmacokinetic and pharmacodynamic properties are influenced by dosage, absorption rate, duration of action, elimination pathway, tissue specificity, and affinity for pancreatic β-cell receptors. Among them, there is a drug that is characterized not only by no less effectiveness in reducing HbA1c, but also by proven advantages in terms of the risk of hypoglycemia, as well as cardiovascular and renal safety-the original gliclazide MR (Diabeton MR®), which is more effective in reducing HbA1c (on average by 1.04%) than representatives of other classes of oral antidiabetic drugs, in particular, DPP4 inhibitors (a decrease of 0.58-0.72%), SGLT-2 inhibitors (decrease by 0.65-1.01%) and thiazolidinediones (decrease by 0.62-0.98%).

Gliclazide MR has a flexible titration and a convenient mode of administration. The drug has a low risk of hypoglycemia, and can be safely used during Ramadan, during fasting. Gliclazide MR also reduces the variability of glycemia. The drug can be combined with other hypoglycemic agents.

Keywords:gliclazide MR, diabetes mellitus, Ramadan, hypoglycemia, safety

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Morgunov L.Yu., Erina E.E. Glyclazide MR: obvious benefits. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (2): 74-81. DOI: https://doi.org/10.33029/2304-9529-2021-10-2-74-81 (in Russian)

REFERENCES

1. Sola D., Rossi L., Schianca G.P.C., Maffioli P, Bigliocca M., Mella R., et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015; 11 (4): 840-8.

2. Alzaid A. Sulfonylureas in the treatment of type 2 diabetes mellitus: a fresh look and new insights. Diabetes Ther. 2020; 11 (suppl 1): 1-3. DOI: https://doi.org/10.1007/s13300-020-00810-4

3. Colagiuri S., Matthews D., Leiter L.A., Chan S.P., Sesti G., Marre M. The place of gliclazide МВ in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018; 143: 1-14. DOI: https://doi.org/10.1016/j.dia-bres.2018.05.028

4. Khunti K., Hassanein M., Lee M.-K., Mohan V., Amod A. Role of gliclazide MB in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives. Diabetes Ther. 2020; 11 (suppl 2): 33-48. DOI: https://doi.org/10.1007/s13300-020-00833-x

5. Riddle M.C., et al. Standards of medical care in diabetes. The American Diabetes Association (ADA). Diabetes Care. 2020; 43 (suppl 1): S 98-110. DOI: https://doi.org/10.2337/dc20-S009

6. Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C., et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43 (2): 487-93. DOI: https://doi.org/10.2337/dci19-0066 Epub 2019 Dec 19.

7. Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010; 89: 126-33.

8. Wong M.G., Perkovic V., Chalmers J., Woodward M., Li Q., Cooper M.E., et al., ADVANCE-ON Collaborative Group. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016; 39: 694-700.

9. Gffide P., Oellgaard J., Carstensen B., Rossing P., Lund-Andersen H., Parving H., et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016; 59: 2298-307.

10. Instructions for medical use of the drug Diabeton MV. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7ca665a-12a9-44d6-a6f5-672069650494&t= (date of access March 23, 2021) (in Russian)

11. Dedov I.I., Shestakova M.V., Mayorov A. Yu., Vikulova O.K., Gal-styan G.R., Kuraeva T.L., et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A. Yu. 9th edition. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (1S 1): 1-144. DOI: https://doi.org/10.14341/DM221S1 (in Russian)

12. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013; 83 (3): 517-23.

13. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358 (24): 2560-72.

14. Lee Y.-H., et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015; 41 (3): 208-15. DOI: http://doi.org/10.1016/j.diabet.2015.01.004

15. Rocco M.V., Berns J.S. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012; 60: 850-86.

16. Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22 (12): 2417-26. DOI: http://doi.org/10.1111/dom.14169

17. Maloney A., Rosenstock J., Fonseca V. A Model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019; 105 (5): 1213-23. DOI: http://doi.org/10.1002/cpt.1307

18. Shestakova M.V., Vikulova O.K. The results of open observational trial DIAMOND. Sakharniy diabet [Diabetes Mellitus]. 2011; 14 (3): 96-102. (in Russian)

19. Leiter L.A., Shestakova M.V., Trubitsyna N.P., Piletic M., Satman I. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract. 2016; 112: 50-6. DOI: http://doi.org/10.1016/j.diabres.2015.11.001

20. Trubitsyna N.P, Shestakova M.V. Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (2): 159-64. DOI: https://doi.org/10.14341/DM10185 (in Russian)

21. Vianna A.G.D., Lacerda C.S., Pechmann L.M., Polesel M.G., Marino E.C., Faria-Neto J.R. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MB (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes. Diabetes Res Clin Pract. 2018; 139: 357-65. DOI: https://doi.org/10.1016/j.dia-bres.2018.03.035

22. Clemens K.K., McArthur E., Dixon S.N., Fleet J.L., Hramiak I., Garg A.X. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Can J Diabetes. 2015; 39 (suppl 4): 32-40. DOI: https://doi.org/10.1016/jjcjd.2015.09.087

23. Salti I., Benard E., Detournay B., Bianchi-Biscay M., Le Brigand C., Voinet C., et al.; EPIDIAR study group. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004; 27: 2306-11.

24. Al-Arouj M., Assaad-Khalil S., Buse J., Fahdil I., Fahmy M., Hafez S., et al. Recommendations for management of diabetes during Ramadan: Update 2010. Diabetes Care. 2010; 33: 1895-902.

25. Kalra S., Gupta Y., Unnikrishnan A.G. Flexibility in insulin prescription. Indian J Endocrinol Metab. 2016; 20: 408-11.

26. Zargar A.H., Siraj M., Jawa A.A., Hasan M., Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract. 2010; 64 (8): 1090-4. DOI: https://doi.org/10.1111/j.1742-1241.2009.02262.x

27. Al-Arouj M., Hassoun A.A., Medlej R., Pathan M.F., Shaltout I., Chawla M.S., et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013; 67: 957-63.

28. Hassanein M., Al Sifri S., Shaikh S., Raza S.A., Akram J., Pranoto A., et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020; 163: 108154.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»